Plain-English translation of NCT07025148 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing , a blood-thinning medication, as an alternative to in patients who have had a heart stent placed and face a difficult balance: they need protection against future heart problems but are also at higher risk of serious bleeding. The study compares two groups—some patients will switch to a lower dose of this medication, while others will continue their current blood thinner—to see which approach works better for patients in this tricky situation.
After a heart stent is placed, patients must take blood-thinning medications to prevent clots, but some people are caught in a difficult situation where standard doses increase their bleeding risk. This trial exists to find out whether using this medication at a lower dose offers better protection with less danger of dangerous bleeding.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to either continue your current blood-thinning medication or switch to the lower-dose alternative. Throughout the study, you will have blood tests to measure how your blood cells are responding to the medication, helping researchers understand which approach is safer and more effective for patients like you. The study involves 40 patients total and focuses on measuring how well each treatment works rather than observing you over a long period.
AI-generated summary from trial data · Aug 6, 2026 · Not medical advice
United States